Drug Profile


Alternative Names: ABT-719; AP-214; ZP-1480

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Action Pharma
  • Developer AbbVie; Action Pharma
  • Class Anti-inflammatories; Melanocyte-stimulating hormones; Peptides; Small molecules
  • Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adult respiratory distress syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute kidney injury; Adult respiratory distress syndrome; Multiple organ failure; Myocardial infarction; Reperfusion injury

Most Recent Events

  • 19 Sep 2014 Discontinued - Phase-II for Acute kidney injury (Prevention) in Denmark (IV)
  • 19 Sep 2014 Discontinued - Phase-II for Acute kidney injury (Prevention) in USA (IV)
  • 01 Jun 2014 AbbVie terminates a phase II trial for Acute kidney injury (prevention) in USA and Denmark (NCT01897519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top